相似文献
1
Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.
J Clin Microbiol. 1999 Sep;37(9):3013-6. doi: 10.1128/JCM.37.9.3013-3016.1999.
2
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
Hepatology. 1999 Nov;30(5):1302-6. doi: 10.1002/hep.510300525.
3
Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
Curr HIV Res. 2011 Jun;9(4):263-9. doi: 10.2174/157016211796320315.
4
HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Antivir Ther. 2017;22(1):13-20. doi: 10.3851/IMP3055. Epub 2016 May 11.
5
Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
Antivir Ther. 2012;17(2):321-6. doi: 10.3851/IMP1911. Epub 2011 Sep 23.
6
Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.
Clin Infect Dis. 2001 Dec 15;33(12):2049-54. doi: 10.1086/322655. Epub 2001 Nov 5.
7
Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations.
Mem Inst Oswaldo Cruz. 2006 Sep;101(6):655-60. doi: 10.1590/s0074-02762006000600013.
8
High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Antivir Ther. 2015;20(5):545-54. doi: 10.3851/IMP2942. Epub 2015 Feb 5.
9
Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
BMC Infect Dis. 2004 Aug 31;4:29. doi: 10.1186/1471-2334-4-29.
10
[Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in human immunodeficiency virus co-infected patients].
Gastroenterol Clin Biol. 2000 Jan;24(1):125-7.
引用本文的文献
1
Baseline characteristics of HIV & hepatitis B virus (HIV/HBV) co-infected patients from Kolkata, India.
Indian J Med Res. 2016 May;143(5):636-42. doi: 10.4103/0971-5916.187113.
2
Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.
J Virol Methods. 2016 Jul;233:51-5. doi: 10.1016/j.jviromet.2016.03.014. Epub 2016 Mar 26.
3
Seroprevalence of Hepatitis B and C Viruses Among Children in Kilimanjaro Region, Tanzania.
J Pediatric Infect Dis Soc. 2013 Dec;2(4):320-6. doi: 10.1093/jpids/pit018. Epub 2013 Apr 12.
4
Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase.
J Biol Chem. 2008 Dec 5;283(49):34218-28. doi: 10.1074/jbc.M806797200. Epub 2008 Oct 20.
5
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
Antimicrob Agents Chemother. 2008 Oct;52(10):3617-32. doi: 10.1128/AAC.00654-08. Epub 2008 Aug 1.
6
Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: characterization of genotype G in Brazil.
BMC Microbiol. 2008 Jan 22;8:11. doi: 10.1186/1471-2180-8-11.
7
HBV plus HCV, HCV plus HIV, HBV plus HIV.
Curr Gastroenterol Rep. 2006 Feb;8(1):67-74. doi: 10.1007/s11894-006-0066-9.
8
Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection.
Antimicrob Agents Chemother. 2005 Jul;49(7):2720-8. doi: 10.1128/AAC.49.7.2720-2728.2005.
9
Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
BMC Infect Dis. 2004 Aug 31;4:29. doi: 10.1186/1471-2334-4-29.
10
Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1.
Eur J Clin Microbiol Infect Dis. 2003 Feb;22(2):92-8. doi: 10.1007/s10096-002-0868-0. Epub 2003 Feb 18.
本文引用的文献
1
The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.
Antivir Chem Chemother. 1998 Jan;9(1):65-72.
2
Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro.
Hepatology. 1998 Dec;28(6):1669-73. doi: 10.1002/hep.510280629.
3
Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.
Biochem Pharmacol. 1998 May 15;55(10):1567-72. doi: 10.1016/s0006-2952(98)00050-1.
4
Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
Hepatology. 1998 Jun;27(6):1711-6. doi: 10.1002/hep.510270634.
5
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.
Hepatology. 1998 Jun;27(6):1670-7. doi: 10.1002/hep.510270628.
6
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment.
J Infect Dis. 1998 May;177(5):1382-5. doi: 10.1086/517819.
7
Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.
Hepatology. 1998 Feb;27(2):628-33. doi: 10.1002/hep.510270243.
8
Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value.
J Hepatol. 1997 Jul;27(1):18-24. doi: 10.1016/s0168-8278(97)80274-7.
9
Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns.
J Hepatol. 1997 Jun;26(6):1393-5. doi: 10.1016/s0168-8278(97)80476-x.
10
Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation.
J Hepatol. 1997 May;26(5):1148-53. doi: 10.1016/s0168-8278(97)80125-0.
Zotero 插件